RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A

Thyroid

Volumn 14, Issue 10, 2004, Pages 813-818

  Yun, Jae Chung ^a   Kim, Hyung Hoon ^a   Kim, Hyun Jin ^a   Min, Yong Ki ^a   Lee, Myung Shik ^a   Lee, Moon Kyu ^a   Kim, Kwang Won ^a   Ki, Chang Seok ^a   Kim, Jong Won ^a   Jae, Hoon Chung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PROTEIN RET;

ADULT; ARTICLE; CLINICAL ARTICLE; CODON; DNA SEQUENCE; EXON; FAMILIAL MEDULLARY THYROID CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KOREA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; CODON; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; ONCOGENE PROTEINS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 8444237040     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2004.14.813     Document Type: Article

References (42)

1. Farndon JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity. Br J Surg 73:278-281.
2. Marsh DJ, Learoyd DL, Robinson BG 1995 Medullary thyroid carcinoma: Recent advances and management update. Thyroid 5:407-424.
3. Gimm O, Sutter T, Dralle H 2001 Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Oncol 127:156-165.
4. Bachelot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M 2002 Inheritable forms of medullary thyroid carcinoma. Biochimie 84:61-66.
5. Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI, Fong SL, Bridges CD, Haak H, Kruseman AC, Schifter S, Hansen HH, Telenius H, Telenius-Berg M, Ponder BAJ 1987 A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (London) 328: 527-528.
6. Simpson NE, Kidd KK, Goodfellow PJ, McDermid H, Myers S, Kidd JR, Kackson CE, Duncan AM, Farrer LA, Brasch K, Castiglione C, Genel M, Gertner J, Greenberg CR, Gusella JF, Holden JAA, White BN 1987 Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature (London) 328:528-530.
7. Norum RA, Lafreniere RG, O'Neal LW, Nikolai TF, Delaney JP, Sisson JC, Sobol H, Lenoir GM, Ponder BA, Willard HF, Jackson CE 1990 Linkage of multiple endocrine neoplasia type 2B gene (MEN2B) to chromosome 10 markers linked to MEN2A. Genomics 8:313-317.
8. Lairmore TC, Howe JR, Korte JA, Dilley WG, Aine L, Aine E, Wells SA Jr, Donnis-Keller H 1991 Familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2B map to the same region of chromosome 10 as multiple endocrine neoplasia type 2A. Genomics 9:181-192.
9. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SAJ 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856.
10. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, More SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A, Ponder BAJ 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (London) 363:458-460.
11. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Kackson CE, Wells SA Jr, Goodfellow PJ, Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad USA 91:1579-1583.
12. Eng C, Smith DP, Mulligan LM, Nagi MA, Healey CS, Ponder MA, Gardner E, Scheumann GFW, Jackson CE, Tunnacliffe A, Ponder BAJ 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumors. Hum Mol Genet 3:237-241.
13. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Hoppener JW, van Amstel HK, Romeo G, Lips CJM, Buys CHCM 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367:375-376.
14. Mulligan LM, Marsh DJ, Robinson BG, Schuffenecker I, Zedenius J, Lips CJM, Gagel RF, Takai SI, Noll WW, Fink M, Raue F, Lacroix A, Thibodeau SN, Frilling A, Ponder BAJ, Eng C 1995 International RET Mutation Consortium. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238:343-346.
15. Frank-Raue K, Hppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F, GMTCS Group 1996 Mutations of the RET proto-oncogene in German MEN families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780-1783.
16. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671.
17. Carlomagno F, Salvatore G, Cirafici AM, De Vita G, Melillo RM, de Franciscis V, Billaud M, Fusco A, Santoro M 1997 The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57:391-395.
18. Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir GM, Santoro M, Billaud M 1998 Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines. Oncogene 17:2851-2861.
19. Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M 1999 Co-segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss-of-function? Hum Mutat 13:331-336.
20. Smith DP, Houghton C, Ponder BA 1997 Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213-1217.
21. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C 1997 Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82:3902-3904.
22. Punales MK, Graf H, Gross JL, Maia AL 2003 RET codon 634 mutations in multiple endocrine neoplasia type 2: Variable clinical features and clinical outcome. J Clin Endocrinol Metab 88:2644-2649.
23. Harm JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11:73-80.
24. American Joint Committee on Cancer 2002 Head and Neck Sites. Thyroid. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds.) AJCC Cancer Staging Manual, 6th ed. Springer-Verlag, New York, pp. 77-87.
25. Eng C, Smith DP, Mulligan LM, Healey CS, Zvelebil MJ, Stonehouse TJ, Ponder MA, Jackson CE, Waterfield MD, Ponder BA 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 10:509-513.
26. Eng C, Mulligan LM 1997 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours and Hirschsprung disease. Hum Mutat 9:97-109.
27. Hansford JR, Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis. J Med Genet 37:817-827.
28. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HPH, Ponder MA, Ponder BAJ 1995 Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123-127.
29. Wohllk N, Cote GJ, Bugalho MM, Ordonez N, Evans DB, Goepfert H, Khorana S, Schultz P, Richards CS, Gagel RF 1996 Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 81:3740-3745.
30. Huang CN, Wu SL, Chang TC, Huang SH, Chang TJ 1998 RET protooncogene mutations in patients with apparently sporadic medullary thyroid carcinoma. J Formos Med Assoc 97:541-546.
31. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B 2001 Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19:1374-1380.
32. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S 2001 Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol 55:399-402.
33. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF 2001 Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chil 129:713-718.
34. Takano T, Miyauchi A, Yoshida H, Hasegawa Y, Kuma K, Amino N 2001 Large-scale analysis of mutations in RET exon 16 in sporadic medullary thyroid carcinomas in Japan. Jpn J Cancer Res 92:645-648.
35. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83:487-491.
36. Ball DW, Baylin SB, De Bustros AC 2000 Medullary thyroid carcinoma. In: Braverman LE, Utiger RD (eds.) Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text, 8th ed. Lippincott Williams & Wilkins, Philadelphia, pp. 930-943.
37. Eng C, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Thomas GA, Ponder BAJ 1996 Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170.
38. Eng C, Thomas G, Mulligan L, Healey CS, Houghton C, Frilling A, Raue F, Williams E, Ponder B 1998 Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 88: 4310-4313.
39. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JBJ, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H, Neumann HPH, Thibodeau SN, Ponder BAJ 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6:70-74.
40. Lee MS, Hwang DY, Kim YH, Chung JH, Oh YS, Lee MK, Kim KW 1998 Mutations of ret proto-oncogenes in 3 Korean families with MEN 2A: Clinical use of new restriction sites for genetic diagnosis. Endocr J 45:555-561.
41. Kim SW, Kim TY, Park YJ, Kim WB, Shin CS, Park DJ, Park KS, Kim SY, Cho BY, Lee HK 2001 Early detection of medullary thyroid cancer by screening of the RET proto-oncogene germ line point mutation in family members affected with hereditary medullary thyroid cancer. J Korean Soc Endocrinol 16:54-64.
42. Kim IJ, Kang HC, Park JH, Ku JL, Lee JS, Kwon HJ, Yoon KA, Heo SC, Yang HY, Cho BY, Kim SY, Oh SK, Youn YK, Park DJ, Lee MS, Lee KW, Park JG 2002 RET oligonucleotide microarray for the detection of RET mutations in multiple endocrine neoplasia type 2 syndromes. Clin Cancer Res 8:457-463.